Kisspeptin-10: research

A short-acting experimental peptide that triggers reproductive hormone release.

Also called: KP-10, KP10, Kisspeptin 112-121, Metastin 45-54, NSC 741805.

Reproductive axis peptides · KISS1 receptor agonist.

38 human research records include ongoing studies and studies without results; some share participants. Most measured short-term hormones, not lasting benefits or long-term safety.

Studies

• A bolus resets LH timing. single-arm, n=13, 13 healthy adult men. One IV dose triggered an LH pulse and delayed the next spontaneous pulse. (source)
• First dose and infusion study. open-label, Overall bolus cohort: 6 healthy men; 4 men in each infusion experiment. IV dosing raised LH and testosterone; these experiments did not test home injection schedules. (source)
• Response depends on sex and cycle. pk-study, n=46, 11 healthy men and 35 healthy women; 4–5 per dose group. KP-10 cleared in minutes; women responded differently across the cycle. (source)
• Cycle phase changes the LH response. single-arm, Healthy women: early follicular n=10, preovulatory n=3, midluteal n=14; four additional higher-dose visits. Responses to the same dose varied by menstrual phase. (source)
• Contraception changes the response. open-label, n=24, 10 follicular-phase, 6 postmenopausal, 4 combined-pill and 4 progestogen-implant users. Combined-pill users had a blunted LH response. (source)
• NKB-deficient patients respond to infusion. open-label, n=4, 3 men and 1 woman with TAC3 or TACR3 loss-of-function variants. Continuous KP-10 restored LH pulses in four selected patients. (source)
• Low testosterone in type 2 diabetes. open-label, n=12, 5 men with type 2 diabetes and low testosterone; 7 healthy comparators; 4 men completed infusion. Hormones rose during an 11-hour infusion in four men with diabetes. (source)
• Most congenital hypogonadism did not respond. open-label, n=12, 11 adults with persistent congenital IHH; one man with reversal. An intact responsive GnRH network was needed for an LH response. (source)
• KP-10 versus KP-54 and GnRH. crossover-rct, n=10, 10 healthy men; 5 participants per dose group, with some crossover between doses. Both kisspeptins raised LH, but GnRH produced a larger response. (source)
• Reversal versus relapse of hypogonadism. case-series, n=6, 6 men with congenital IHH and prior spontaneous reversal. KP-10 response tracked whether natural LH pulses had returned. (source)
• Estrogen and NKB feedback. crossover-rct, n=20, 20 healthy women: 10 with NK3R blockade and 10 without. Estrogen and NKB signaling changed how long the LH rise lasted. (source)
• GnIH co-infusion in men. crossover-rct, n=4, 4 healthy men in the KP-10 experiment; 5 postmenopausal women had GnIH alone. GnIH did not reduce KP-10-induced LH release in four men. (source)
• 24-hour infusion after menopause. open-label, n=8, 8 postmenopausal women; 4 off estradiol, 7 on estradiol; 3 did both. Estradiol altered the response to sustained KP-10 exposure. (source)
• NKB blockade in men. open-label, n=6, 6 healthy men. KP-10 still stimulated LH despite NKB receptor blockade. (source)
• Infusion in two women with high prolactin. case-series, n=2, Two women with cabergoline-resistant microprolactinomas and chronic absent periods. A 12-hour infusion increased reproductive hormones in two women. (source)
• NKB blockade after menopause. open-label, n=11, 11 postmenopausal women. KP-10 did not raise LH in this postmenopausal cohort. (source)
• Delayed puberty: early response study. open-label, n=20, 15 children with delayed puberty; 5 healthy adult male comparators. Response varied widely in children with delayed puberty. (source)
• Response across puberty stages. open-label, n=30, 25 boys: 5 per Tanner stage; 5 adult men. The strongest LH response appeared late in puberty. (source)
• Sex steroids did not restore response. case-series, n=7, 6 men and 1 woman with congenital IHH. Sex-steroid replacement did not make congenital IHH responsive. (source)
• Aging and the testosterone response. open-label, Healthy adult, middle-aged and older men; registry enrollment 15. Older men had less testosterone response despite an LH rise. (source)
• Kisspeptin and opioid blockade in TAC3 loss. case-series, n=5, Five related women; four had TAC3 deficiency; three received KP-10 boluses. Kisspeptin responses persisted despite absent NKB signaling. (source)
• Irisin after a single dose. open-label, n=16, 8 normal-weight and 8 obese men. Irisin rose after dosing, but weight-loss effects were not tested. (source)
• Delayed puberty: later outcomes. cohort, n=16, 16 children previously tested for delayed puberty. The earlier LH response predicted pubertal progression in this small cohort. (source)
• PCOS: KP-10 with NKB blockade. crossover-rct, n=10, 10 unique women with PCOS; 8 had antagonist pretreatment and 7 had no pretreatment, with 5 women in both conditions. KP-10 still raised LH after NKB blockade in PCOS. (source)
• Hourly boluses with high prolactin. open-label, n=11, 11 women with hyperprolactinemia. Hourly IV doses increased LH pulse frequency. (source)
• Oxytocin rose more in men. single-arm, n=12, 12 healthy adults: 6 men and 6 women. A brief oxytocin rise was larger in men. (source)
• No vasopressin rise. single-arm, n=12, The same 12 healthy adults as the oxytocin report. This dose did not work as a vasopressin stimulation test. (source)
• 24-hour infusion in three men. single-arm, n=3, 3 healthy adult men. LH rose strongly, then declined during continued exposure. (source)
• SC infusion for up to 12 days. crossover-rct, n=15, 15 healthy men recruited; substudies n=7, 4 and 7; 12 men served as controls. Intermittent pump dosing retained hormone effects for 12 days. (source)
• SC high-prolactin registry results. open-label, n=36, 36 consented women: 21 IV and 15 SC; outcomes available for 11 IV and 5 SC. Registry SC results show follicle growth in three of five analyzed women. (source)
• 40-hour repeated bolus results. single-arm, n=18, 18 enrolled with hypogonadotropic hypogonadism; 7 completed the intervention. Repeated-bolus registry results are small and include a serious event after study visits. (source)
• Glucose-tolerance registry results. crossover-rct, n=16, 16 consented adults; 11 began, 9 completed both visits. The posted glucose-sensitivity values were similar to placebo. (source)
• Insulin after a bolus. single-arm, n=14, Normal-weight and obese men. Completed; no registry results posted. (source)
• SC reproductive-disorder pilot. open-label, n=13, Women with hypothalamic amenorrhea; actual enrollment 13. Completed, 13 enrolled; no results posted. (source)
• SC pump in congenital hypogonadism. open-label, Adults with IHH. Recruiting; target 36; no results posted. (source)
• SC pump in absent periods. open-label, Women with hypothalamic amenorrhea. Recruiting; target 20; no results posted. (source)
• New GnRH-function study. single-arm, Adults with post-COVID-19 syndrome and healthy comparators. Recruiting; target 40; no results posted. (source)
• Continuous dosing in PCOS. single-arm, n=8, Adults with polycystic ovary syndrome; actual enrollment 8. Completed, 8 enrolled; no results posted. (source)
• Genotype-recall trial stopped. single-arm, n=16, Biobank participants. Terminated after loss of access to study drugs; 16 consented, zero exposed. (source)
• Glucose study withdrawn before enrollment. single-arm, No participants enrolled. The trial never enrolled participants. (source)
• Glucose study withdrawn before enrollment. single-arm, No participants enrolled. The trial never enrolled participants. (source)
• Weight gain and estrone: one safety report. case-report, n=1, 17-year-old boy with hypogonadotropic hypogonadism. One incomplete spontaneous report cannot establish a side-effect rate. (source)
• Dog safety study. animal, Dogs given IV KP-10. A short dog study found no overt toxicity at its tested doses. (source)
• Plaque progression in susceptible mice. animal, ApoE-deficient mice and human vascular cells. KP-10 worsened plaque biology in a susceptible mouse model. (source)
• Contraction in isolated human vessels. in-vitro, Human coronary-artery and umbilical-vein rings, outside the body. KP-10 contracted isolated human blood vessels. (source)
• Breast-cancer cell signaling. in-vitro, MDA-MB-231 and Hs578T human breast-cancer cells. Cancer effects can depend on cell type and signaling context. (source)

Gaps: No large trial establishes durable libido, fertility, symptom or testosterone benefits from home KP-10 bolus injections. Long-term safety, immune reactions, cancer risk and cardiovascular outcomes are unknown. No repeated daily, alternate-day or weekly SC bolus maximum has been established; pump rates are not bolus limits. Some registry doses are undisclosed. Per-person titrations and low-dose outcomes shown only in plots were not reconstructed. Community prevalence is qualitative, not a survey. Most hormone claims lack verifiable laboratory records. No validated oral, troche, IM or intranasal KP-10 schedule, or home reconstitution expiry, was found. EU national approvals, UK personal-import rules and Australian KP-10 scheduling remain incompletely verified. Published reports reuse participants; study counts are not independent exposure counts. Registry adverse-event grades were not posted. Display severity bands are symptom triage categories, not measured trial grades.

Related to Kisspeptin-10

• Gonadorelin: A short-acting fertility hormone used in tests and specialist pump therapy.
• hCG: A fertility hormone with limited testosterone add-on evidence and no proven weight-loss benefit.
• Bremelanotide: An as-needed injection for low libido before menopause; nausea is common.
• Hexarelin: A peptide that releases growth hormone; repeated use can weaken the response.

Kisspeptin-10: the short version

Sources

• Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
• Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
• Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
• Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
• Medicines, European Medicines Agency · European Medicines Agency · 2026
• The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
• Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
• Supply unlicensed medicinal products (specials), MHRA · 2025
• October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee
• October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting
• Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risks, Health Canada
• Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men., Yeung AC et al. · European journal of endocrinology · 2026
• Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men., Naveed A et al. · Hormones (Athens, Greece) · 2026
• Intravenous kisspeptin 112-121 bolus does not acutely impact circulating vasopressin in humans., Galbiati F et al. · Journal of neuroendocrinology · 2026
• Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans., Mills EG et al. · EBioMedicine · 2025

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.